Is Octreotide (Sandostatin) legal?
Octreotide (Sandostatin) is an FDA approved drug. For drug-tested athletes it is not on the WADA prohibited list. Yes, endocrinology and oncology providers prescribe for the approved indications.. Legal status depends on your country and changes over time. This reflects US status at the time of writing and is not legal or medical advice.
Regulatory status
- FDA: Approved as Sandostatin (1988) for acromegaly, carcinoid syndrome, and VIPomas. Available in immediate-release sub-q and long-acting (LAR) IM depot.
- WADA: Not listed
- Prescription: Yes, endocrinology and oncology providers prescribe for the approved indications.
References
- Octreotide therapy for acromegaly, long term outcome — Mercado M et al., JCEM, 2014
- Sandostatin LAR Depot (octreotide acetate) - FDA Label — FDA / DailyMed (Novartis Pharmaceuticals)
- Preoperative somatostatin analogues versus direct transsphenoidal surgery for newly-diagnosed acromegaly patients: a systematic review and meta-analysis using the GRADE system — Nunes VS et al., Pituitary, 2015
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on Octreotide (Sandostatin)
Last updated 2026-06-06.